Specificity of Subcapsular Antibody Responses in Ethiopian Patients following Disease Caused by Serogroup A Meningococci
Open Access
- 1 May 2008
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 15 (5) , 863-871
- https://doi.org/10.1128/cvi.00252-07
Abstract
Dissecting the specificities of human antibody responses following disease caused by serogroup A meningococci may be important for the development of improved vaccines. We performed a study of Ethiopian patients during outbreaks in 2002 and 2003. Sera were obtained from 71 patients with meningitis caused by bacteria of sequence type 7, as confirmed by PCR or culture, and from 113 Ethiopian controls. Antibody specificities were analyzed by immunoblotting (IB) against outer membrane antigen extracts of a reference strain and of the patients' own isolates and by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) levels against lipooligosaccharide (LOS) L11 and the proteins NadA and NspA. IB revealed that the main antigens targeted were the proteins PorA, PorB, RmpM, and Opa/OpcA, as well as LOS. MenA disease induced significant increases in IgG against LOS L11 and NadA. The IgG levels against LOS remained elevated following disease, whereas the IgG anti-NadA levels returned to acute-phase levels in the late convalescent phase. Among adults, the anti-LOS IgG levels were similar in acute-phase patient sera as in control sera, whereas anti-NadA IgG levels were significantly higher in acute-phase sera than in controls. The IgG antibody levels against LOS and NadA correlated moderately but significantly with serum bactericidal activity against MenA strains. Future studies on immune response during MenA disease should take into account the high levels of anti-MenA polysaccharide IgG commonly found in the population and seek to clarify the role of antibodies against subcapsular antigens in protection against MenA disease.Keywords
This publication has 83 references indexed in Scilit:
- Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle VaccinesClinical and Vaccine Immunology, 2007
- Serum Antibody Responses in Ethiopian Meningitis Patients Infected withNeisseria meningitidisSerogroup A Sequence Type 7Clinical and Vaccine Immunology, 2007
- Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adultsVaccine, 2007
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences, 2006
- Characterization of Neisseria meningitidis Isolates from Recent Outbreaks in Ethiopia and Comparison with Those Recovered during the Epidemic of 1988 to 1989Journal of Clinical Microbiology, 2006
- Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidisVaccine, 2005
- Development of Immunity to Serogroup B Meningococci during Carriage of Neisseria meningitidis in a Cohort of University StudentsInfection and Immunity, 2004
- Meningococcal meningitis in AfricaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1999
- Purification of meningococcal lipooligosaccharide by FPLC techniquesMicrobiology, 1996
- Antibodies against IgAl Protease Are Stimulated Both by Clinical Disease and Asymptomatic Carriage of Serogroup A Neisseria meningitidisThe Journal of Infectious Diseases, 1992